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Tolterodine tartrate, is a new, potent and competitive muscarinic receptor antagonist in clinical development for 
the treatment of urge incontinence and other symptoms of unstable bladder. The purpose of this study is to 
formulation and invitro evaluation of Tolterodine tartrate by high performance liquid chromatography with 
ultraviolet detection (HPLC-UV). A simple, rapid, and sensitive high-performance liquid chromatographic 
method was developed and evaluated for invitro formulation of Tolterodine tartrate Tablets. Tablets were 
analysed by measuring different parameters: lubricated granules content of Tolterodine tartrate having bulk 
density, tap densities and angle of repose And flim coated Tolterodine tartrate tablets having friability, 
thickness, hardness, weight variation, invitro dissolution,  
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content uniformity, assay and related substances. Separation of Tolterodine tartrate was achieved within a single 
chromatographic run on 5µm 4.6x250mm with UV detection at 280 nm, under isocratic conditions, using 
Acetonitrile and A mixture of 65 volumes of buffer solution prepared by mixing 2.2 ml of orthophosphoric acid 
to 1000 ml with water, adjusted to pH 3.0 with triethylamine in 35:65 ratio with a flow rate of 1.5 ml/min. From 
the results, it was clear that designed formulations among f7 displayed drug release in the range of 55.66% to 
102.067% in 10 min, which showed improved invitro dissolution rate compared to other formulations as well as 
others parameters were found to be good as compared to other formulations. Similarly, the average content of 
formulation f7 was found to be 104.58% and Related substances should comply the test. Assays of f7 were found 
to be 96.04%, the limit is 90% - 110% of the label claim having weight variation range from  82.50 mg-91.50 
mg. 
Keywords: Tolterodine tartrate; HPLC; Assay; Dissolution.  
1. Introduction 
The new potent and competitive muscarinic receptor antagonist in the form of Tolterodine tartrate,(R)-N,N-
diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanaminel-hydrogen tartrate , is armour of clinical 
development for the treatment of urge incontinence and other symptoms of unstable bladder (1-3). Tolterodine 
builds tolerability profile in case of the low frequency of bothersome dry mouth; As It has high affinity and 
specificity for muscarinic receptors in vitro and exhibits the selectivity for the urinary bladder over salivary 
glands in vivo (4). A major pharmacologically active metabolite, 5-hydroxymethyl derivative is formed after 
telterodine is metabolized in liver following the oral administration [5].  The proper dosage form of the drug is 
required to ensure it's optimum therapeutic effect. Solubility is an important characteristic for the drug as 
systemic absorption is affected by dissolution since only dissolved drug can pass the gastrointestinal membrane. 
Oral administration of any drug is the simplest, most common and easiest route, because of small bulk, stability, 
ease in manufacturing as well as ingesting and maintenance of accurate dosage as per required. Poorly water 
soluble drugs with slow drug absorption assists to inadequate as well as variable bioavailability and 
gastrointestinal mucosal toxicity. Designing the oral dosage forms is an uphill task due to poor oral 
bioavailability of the drug. Low solubility, low dissolution of the drug is the main reason of poor oral 
bioavailability of the drug instead of pervasion of drug through epithelia of gastrointestinal tract [6]. Poor 
aqueous solubility and poor membrane pervasion of drug molecule contributes to limitation of drug absorption 
from Gastrointestinal tract. Oral intake of an active agent should first dissolve in gastric and/or intestinal fluids 
before it permeates GI tract membranes onto system circulation. Enhancement of solubility and dissolution rate 
alongside permeability of poorly water soluble drugs is a major challenge pharmaceutical field in improvement 
of oral bioavailability of active agents. Thus, most of the under development chemical entities are targeted to be 
used in the form of solid dosage as an effective reproducible in vivo plasma concentration under oral 
administration [7]. In this study, we describe a comparative study of tablet with marketed drug by using high 
performance liquid chromatography for the determination of stable Tolterodine tartrate Tablets.  
 




2. Materials and Methods 
Tolterodine tartrate (AR No.Poo12456 TOl, C26H37NO7, and MicroCrystalline Cellulose, 102 Lactose 
monohydrate, Calcium Hydrogen Phosphate Dihydrate, Sodium Starch glycollate, Magnesium Stearate, 
colloidal anhydrous silica and Filmcoat universal were obtained from Time Pharma Pvt. Ltd. as a gift sample 
were provided by our Shree Medical and Technical College, Bharatpur-12, Chitwan. 
2.1 Method of Preparation of film coated tablets 
The direct compression method was employed to prepare film coated tablets of tartrate using different 
excipients, such as Microcrystalline cellulose 102, lactose monohydrate, 100 and Carbopol-940, in different 
ratios. 
2.2 Preparation 
MCC 102 was sieved through mesh # 80 and mix with Tolterodine tartrate. The calcium hydrogen phosphate 
dehydrate, sodium starch glycollate and lactose monohydrate were sieved through # 60 and mix with the above 
mixer of Tolterodine tartrate and MCC p 102 and the mixer was sieved through #60 for two times. The content 
was lubricated with already sieved mixer of Magnesium stearate and Colloidal silicon dioxide through #60 mesh 
size for 5 min in RMG. The moisture content was measured which was found to be 5.78%. And compression of 
the tablet was done at 85 mg tablet to a hardness of 6-11 kg/cm
2
 using a 6.5 mm punch according to SOP and 
finally the compressed tablets were coated by preparing coating solution of Flimcoat Universal which was 
dissolved in purified water passing through # 60 mesh size, the coating solution was allowed to soak for 20 
minutes. Finally the filmcoated tablet of Tolterodine tartrate was obtained.  
2.3 Evaluation of Lubricated content of Tolterodine tartrate 
All the prepared tablets were evaluated for the following parameters. 
2.4 Bulk density and Tap densities 
Exactly 50 gm of powder blend were weighed on a chemical balance and transferred into a 100 ml measuring 
cylinder. The cylinder was dropped on a wooden plat form from a height of 2.5 cm three times at 2 second 
intervals. The volume occupied by the granules was recorded as the bulk volume. The cylinder was then tapped 
on the wooden platform until the volume occupied by the powder blend remains constant. This was repeated 
three times for the blend. The data generated was used in calculating Carr’s compressibility index and Haunser’s 
ratio [5]. 
              
    
               
 
               
    
             
 




2.5 Angle of repose  
Fifty grams of powder blend was placed in a plugged glass  funnel that had a distance of 10 cm from the flat 
surface. The blend was then allowed to flow through the 8 mm funnel orifice by removing the cotton plug from 
the funnel orifice. The height of the heap (h) formed as well as the radius of the heap (r) was noted [5]. 





‘θ’ is the angle of repose 
‘h’ is height of pile 
‘r’ is the radius of the base of the pile 
Carr’s Index 
The compressibility index of the granules was determined by Carr’s index. Carr’s index can be calculated by 
using the following formula [8]: 
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)      
2.6 Hausners Ratio 
The Hausners ratio is the indication of the compressibility of a power. The Hausners ratio of the mixed powder 
was calculated by the following formula [8]: 
               
   
                
 
3. Evaluation of Flim coated Tolterodine tartrate tablets 
Friability 
Friability is the measure of tablet strength. A Roche-type friabilator was used for testing the friability using the 
following procedure. Twenty tablets were weighed accurately and placed in the tumbling apparatus that revolves 
at 25 rpm dropping the tablets through a distance of six inches with each revolution. After 4 min, the tablets 
were weighed, and the percentage loss was determined [12]. 
% loss = (Initial weight- final weight) 
* 1oo 






Hardness was measured using a Campbell (HT-100TP) hardness tester. For each batch, three tablets was tested 
[7]. 
Thickness 
Three tablets were selected randomly from each batch, and thickness was measured by using a vernier caliper 
[7]. 
4. Weight Variation 
Twenty tablets were randomly selected from each batch and individually weighed. The average weight and 
standard deviation of 20 tablets were calculated. The batch passed the test for the weight variation test if not 
more than two of the individual tablet weights deviated from the average weight by more than the percentage 
shown in Table No. 3 and none deviated by more than twice the percentage shown [7]. 
Table 1: Percentage deviation allowed under the weight variation test 
S.N Average wt. of Tablets (mg) Percentage 
1.  130 or less 10 
2.  130-324 7.5 
3.  More than 324 5 
In vitro dissolution studies 
The release of the drug from the Tolterodine tartrate tablet was determined using a IP dissolution apparatus, and 
the dissolution rate was studied using 900 ml of gastric juice artificial prepared by dissolving 2 g of sodium 
chloride in 80 ml of 1M hydrochloric acid and dilute to 1000 ml with water [IP 2018]. 
Assay 









Mobile phase A mixture of 65 volumes of buffer solution prepared by mixing 2.2 ml of orthophosphoric 
acid to 1000 ml with water, adjusted to pH 3.0 with triethylamine and 35 volumes of 
acetonitrile 
Flow rate: 1.5 ml/minute 
Wavelength: 280 nm 
Column:  4.6mm*25cm; 5µm,C18  
Injection volume : 20µl 
4.2 Test solution 
Weight and powder 20 tablets. Disperse a quantity of powder containing 10 mg of tolterodine tartrate in 70 ml 
of mobile phase with the aid of ultrasound for 20 minutes and dilute to 100.0 ml with the mobile phase, filter.  
4.3 Reference Solution 
A 0.01 percent w/v solution of tolterodine tartrate RS in the mobile phase. 
4.4 Procedure 
Inject the reference solution, the test is not valid unless the column efficiency is not less than 2000 theoretical 
plates, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not 
more than 2.0 percent  
Inject the reference solution and test solution.  
4.5 Related substances 
Solvent mixture: Equal volumes of mobile phase A and mobile phase B 
Test solution: disperse a quantity of powdered tablets containing 10 mg of tolterodine tartrate in 1 ml of 
methanol 5 ml of the solvent mixture with the aid of ultrasound and dilute to 10 ml with the solvent mixture, 
filter 
4.6 Reference solution 
(a) A 0.001 percent w/v solution of tolterodine tartrate RS prepared by dissolving in methanol and dilute 
with the solvent mixture. 
(b) A 0.03 percent w/v solution of tartaric acid in the solvent mixture. 
 
 





Mobile phase Dissolve 6.8 g of potassium dihydrogen orthophosphate in 1000 ml water, adjusted to pH 
3.5 with orthophosphoric  
Flow rate: 1 ml/minute 
Wavelength: 215 nm 
Column:  4.6mm*25cm; 5µm,C18  
Injection volume : 20µl 
Table 7 
Time (in min) Mobile phase A(percent v/v) Mobile phase B(percent v/v) 
0 65 35 
5 65 35 
20 50 50 
40 30 70 
50 65 35 
Inject the reference solution a the test is not valid unless the column efficiency is not less than 2000 theoretical 
plates and the ailing factor is not more than 2.0 Inject the reference solution (a), (b) and the test solution. in the 
chromatogram obtained with the test solution the area of the principal peak in the chromatogram obtained with 
the reference solution (a) (1 percent) the sum of the areas of all the secondary peaks is not more than twice the 
area of the principal peak in the chromatogram obtained with the reference solution (a) (2.0 percent) . Ignite the 
peak due to tartaric acid corresponding to the peak in the chromatogram obtained with reference solution (b) 
Table 1: Composition of different formulations 
Ingredients mg/tablet Formulation  code             
  F1 F2 F3 F4 F5 F6 F7 
Tolterodine tartrate 1.005 1.005 1.005 1.005 1.005 1.005 1.005 
MCCp 102 62.12 74 76 … …. …. (A) 
Lactose monohydrate 12.00 …. …. 77 67 75.415 (B) 
Calcium hydrogen 
phosphate dehydrate 4.98 4.98 2.915 3.80 5.00 4.98 4.98 
Sodium starch glycollate 4.795 4.915 4.915 3.095 11.895 3.50 3.50 
Colloidal anhydrous silica 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
Magnesium stearate 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
Total 85(mg) 85(mg) 85(mg) 85(mg) 85(mg) 85(mg) 85(mg) 
 




5. Results  
Evaluation of active Tolterodine tartrate 
Moisture content 
Moisture content was found to be 5.78%. 
Assay 
Assays of f7 were found to be 96.04%, the limit is 90% - 110% of the label claim according to IP. 
Evaluation of the developed formulation 
The powder blend of the formulated product was checked for particle size distribution,  
<150 μ= 56.20, 150-250μ = 44.80, >250μ = 0 
Evaluation of Tolterodine tartrate tablets 
Physiochemical Properties 
The weight, thickness, hardness, and friability of the tablets of furosemide were determined. The hardness was 
in the range of 5 to 11 kg/cm
2
. Friability was in the range of 0.32 to 0.67% less than 1%, indicating good 
mechanical strength to withstand the rigors of handling and transportation, and thickness was in the range of 2.9 
mm to 3 mm. The weights of the film coated tablets were found to be in the range of 82.5 to 91.5 mg. which 
were showed in table 2 










Friability Thickness Assay Weight 
variation 
F1 25 9.5 0.27 2.5 80.99 70.09-65.77 
F2 24 4.4 0.23 2.3 79.77 80.00-69.02 
F3 28 5.7 0.22 2.1 68.09 77.9-80.00 
F4 27 7.1 0.47 2.8 76.09 79.54-80.10 
F5 23 8.3 0.39 2.9 88.98 70.10-79.00 
F6 30 9.7 0.50 2.9 89.23 60.98-77.98 
F7 28 10 0.67 3.0 96.04 82.50-91.50 
In-Vitro Dissolution Study 




The cumulative percentage of drug released from the different formulations was given in Table 3.  
Table 3: Dissotution Profile of Formulated Tolterodine Tartrate Products 
      Cumulative % drug release     
Time F1 F2 F3 F4 F5 F6 F7 
10 min 76.11 55.66 60.38 69.05 78.92 89.051 102.067 
Content Uniformity 
Uniformity of Content of Tolterodine tartrate tablets of different formulations were recorded in table 4, 
formulation f7 was found to be good, the average content of formulation 7 was 104.58%.  
Table 4: Uniformity of content of different formulations 




tartrate) F1 F2 F3 F4 F5 F6 F7 
 
76.11 78.66 69.38 70.05 78.12 80.051 104.58 
Related Substance 
The individual impurity was found to be 0.0111% and total impurity was reported 0.0200% for the formulation 
f7 
6. Discussion 
Tablets of Tolterodine tartrate were prepared by the direct compression method using different excipients such 
as MCCP 102, Lactose, Dicalcium Hydrogen Phosphate Dihydrate, Sodium starch Glycollate etc  in different 
ratios. According to the work plan, the tablets were evaluated for their appearance, thickness, hardness, 
friability, weight variation, content uniformity, and related substances and in vitro release. The results of granule 
evaluation suggest that all the granules exhibit good flow properties, as the angle of repose values was less than 
30. The weights of the tablets were found to be uniform. The hardness was in the range of 5 to 11 kg/cm3, 
Friability was in the range of 0.32 to 0.67% less than 1%, indicating good mechanical strength to withstand the 
rigors of handling and transportation, and thickness was in the range of 2.9 mm to 3 mm. The weights of the 
film coated tablets were found to be in the range of 60.98 to 91.5 mg from the above result the formulation f7 
was good due to all the tablet parameters of hardness thickness weight variation as compare to other 
formulations. In vitro release studies were carried out in IP tablet dissolution test appratus-I employing a paddle 
at 50 rpm and 900 ml of gastric juice artificial as dissolution medium. The in vitro dissolution data of all the 
designated formulations are shown in tables 3 from dissolution data, it was evident that designed formulations 
displayed drug release in the range of 55.66% to 102.067% in 10 min. In vitro drug release data showed that 
formulation f7 good in percentage drug release and drug dissolution profile and also better in content uniformity 




as compare to other formulations.  
7. Conclusion 
From the present study, the following conclusions can be drawn: Filmcoated tablets of Tolterodine tartrate can 
be prepared by the direct compression method using MCCP 102 and lactose in definite ratio Magnesium stearate 
and colloidal anhydrous silica act as lubricating agent, which showed acceptable hardness of the prepared 
tablets. All the prepared tablet formulations were found to be good without capping and chipping. As the 
amount of lactose and MCCP 102 indefinite proportion showed the good parameters of tablet formulations, 
tablets were coated with Filmcoat Universal coating solution prepared by soaking with purified water for 20 
minutes. 
8. Limitation of the study 
 Accelerated and real time study of the formulation was not done. 
 Comparative study with marked product was not done 
9. Recommendation for future work 
 Stability study of the formulated product can be conducted. 
 Optimization of formulations. 
 Comparison with marked product can be conducted 
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